{"nct_id":"NCT00726869","title":"A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.","status":"TERMINATED","status_verified_date":"2012-06","start_date":"2008-05","start_date_type":null,"primary_completion_date":"2012-03","primary_completion_date_type":"ACTUAL","completion_date":"2012-03","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["ABT"]}